AGT 190
Alternative Names: AGT-190; HIR MAb-GDNF fusion proteinLatest Information Update: 28 Jul 2025
At a glance
- Originator ArmaGen Technologies
- Class Antiparkinsonians; Immunoglobulin fusion proteins; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action Glial cell line-derived neurotrophic factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease; Stroke
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV, Injection)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Stroke in USA (IV, Injection)
- 08 Jun 2021 Preclinical trials in Parkinson's disease in USA (IV) (ArmaGen Technologies pipeline, June 2021)